UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...
Despite the notable advancements in cancer pharmacotherapy, such as chemotherapy, targeted therapy, and immunotherapy, which have significantly improved patient survival rates, managing the associated ...
The fake medicine, bearing a manufacturing date of March 2024 and an expiry date of February 2027, has since been recalled by the agency, warning caregivers and the public to be cautious of the drug ...
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to ...
Other possible serious side effects include inflammation of the pancreas, low blood sugar, allergic reactions, kidney problems, gallbladder issues, stomach paralysis, thyroid tumors, or cancer.